// App-Quantinova.ai

26 : Concordance of BRCA1, BRCA2 (BRCA), and ATM mutations identified in matched tumor tissue and circulating tumor DNA (ctDNA) in men with metastatic castration-resistant prostate cancer (mCRPC) screened in the PROfound study.

Researchers

Presenter

  • Kim N. Chi

Principal Investigators

  • Alan Barnicle

  • Caroline Sibilla

  • Zhongwu Lai

  • Claire Corcoran

  • J. Andrew Williams

  • J Carl Barrett

  • Carrie A. Adelman

  • Ping Qiu

  • Ashley Easter

  • Simon Dearden

  • Elizabeth Harrington

Medical Centers

  • BC Cancer Agency, Vancouver, BC, Canada

  • AstraZeneca Translational Medicine, Early Oncology, Cambridge, United Kingdom

  • AstraZeneca, Precision Medicine and Biosamples, Cambridge, United Kingdom

  • AstraZeneca, Translational Medicine, Waltham, MA

  • Merck Research Laboratories, Translational Molecular Biomarkers and Companion Diagnostics, Kenilworth, NJ

  • AstraZeneca Oncology Business Unit, Cambridge, United Kingdom

Locations

  • Canada

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Breast cancer type 1 susceptibility protein

  • Breast cancer type 2 susceptibility protein

  • BRCA mutation

  • Circulating DNA

  • Ataxia-telangiectasia mutated

Drug/Treatment

  • Methadone hydrochloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT02987543

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved